10 Most Undervalued Biotech Stocks to Buy Now

5. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Forward P/E: 10.16

Number of Hedge Fund Holders: 31

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $75 from $72, keeping a Buy rating on the shares.

The rating update came after Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported its fiscal Q2 2025 results.

The analyst told investors in a research note that Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its fiscal 2025 guidance for the third time this year following another quarter of solid results.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported its fiscal Q2 2025 results on August 5, with total revenue increasing 41% year-over-year to $326 million and royalty revenue growing 65% year-over-year to $206 million.

Net income for the quarter rose 77% year-over-year to $165 million, while adjusted EBITDA increased 65^ year-over-year to $226 million.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology.

They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.